Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis [Phase 3]
Phase 3 trial update evaluating long-term safety and efficacy of tildrakizumab in psoriatic arthritis; the study is ongoing but not currentl…
-
EMA approval · 2026-03-04EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.
The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis [NA]
This source provides a clinical trial update on a study evaluating biologic and anti-obesity therapies for psoriatic arthritis; the trial st…
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2026-02-24EMA Authorised: Fymskina (ustekinumab) — Formycon AG
The EMA authorised Fymskina, an ustekinumab biosimilar from Formycon AG, for Crohn's disease, psoriasis, and psoriatic arthritis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
A clinical trial evaluating guselekumab for shared pathways in psoriasis, psoriatic arthritis, and nonalcoholic fatty liver disease has been…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
This clinical trial aims to evaluate clinical and immune responses to sequential biologic therapies in psoriatic arthritis and is currently …
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-18EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC
EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Cr…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Modifying PEST for Psoriatic Arthritis Screening [NA]
Clinical Trial Update noting modifications to the Psoriasis Epidemiology Screening Tool (PEST) for screening Psoriatic Arthritis, sponsored …
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA) [NA]
This entry reports the completed status of a University of Pennsylvania–sponsored clinical trial evaluating telemedicine to address off-targ…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
A non-US clinical trial is currently recruiting to evaluate treatment persistence with risankizumab in adults with psoriatic arthritis.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Psoriatic Arthritis and Psoriasis Treatment Decision Aid [NA]
University of Pennsylvania-sponsored clinical trial evaluating a treatment decision aid for psoriatic arthritis and psoriasis has completed.
-
EMA approval · 2026-02-16EMA Authorised: Yesintek (ustekinumab) — Biosimilar Collaborations Ireland Limited
The European Medicines Agency authorised Yesintek, a biosimilar of ustekinumab, for use in psoriasis, psoriatic arthritis, and Crohn's disea…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Rheumatology Patient Registry and Biorepository
This Clinical Trial Update describes a Yale University-led rheumatology patient registry and biorepository that is currently recruiting to c…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System [NA]
Post-market clinical follow-up study of the A.L.P.S. Proximal Humerus Plating System by Zimmer Biomet is currently ACTIVE_NOT_RECRUITING, ex…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
A completed clinical trial evaluating adverse events and changes in disease symptoms in Korean participants with rheumatoid arthritis, atopi…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis [Phase 2]
A Phase II clinical trial evaluating the efficacy and safety of TQH3906 capsules for active psoriatic arthritis; the study is not yet recrui…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis [NA]
A clinical trial is exploring transcranial magnetic stimulation to modulate the brain-immune axis for chronic pain in psoriatic arthritis, w…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) [Phase 4]
This Phase 4 clinical trial evaluates the effectiveness of tirzepatide after initiation of ixekizumab in adults with active psoriatic arthri…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Apremilast and Adalimumab in Psoriatic Arthritis Patients [NA]
A clinical trial evaluating apremilast and adalimumab for psoriatic arthritis is not yet recruiting and includes ultrasound assessment.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry
This clinical trial update describes enrollment in the Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry, an observationa…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…